The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Better Therapeutics Inc. shares valued at $20,846 were purchased by Armanino Andrew J. on Jun 14. At $1.39 per share, Armanino Andrew J. acquired 15,000 shares. The insider’s holdings grew to 15,000 shares worth approximately $27600.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Parker Geoffrey M. purchased 25,000 shares, netting a total of over 36,182 in proceeds. Following the buying of shares at $1.45 each, the insider now holds 40,000 shares.
Before that, Heinen Mark had added 5,000 shares to its account. In a trade valued at $7,800, the insider bought Better Therapeutics Inc. shares for $1.56 each. Upon closing the transaction, the insider’s holdings increased to 5,000 shares, worth approximately $36800.0.
As published in their initiating research note from Chardan Capital Markets on November 24, 2021, Better Therapeutics Inc. [BTTX] has been a Buy and the price target has been revised to $17. This represents a 89.18% premium over Wednesday’s closing price. Analysts at Cowen started covering the stock with ‘”an Outperform”‘ outlook in a report released in early November.
Analyzing BTTX’s Price Performance
On Wednesday, Better Therapeutics Inc. [NASDAQ: BTTX] rose 23.49% to $1.84. The stock’s lowest price that day was $1.50, but it reached a high of $2.00 in the same session. During the last five days, there has been a surge of approximately 32.85%. Over the course of the year, Better Therapeutics Inc. shares have dropped approximately -60.43%. Shares of the company reached a 52-week high of $5.1300 on 01/06/22 and a 52-week low of $0.9120 on 04/29/22. A 50-day SMA is recorded $1.6277, while a 200-day SMA reached $5.0671. Nevertheless, trading volume fell to 1.63 million shares from 0.25 million shares the previous day.
Support And Resistance Levels for Better Therapeutics Inc. (BTTX)
According to the 24-hour chart, there is a support level at 1.5600, which, if violated, would cause prices to drop to 1.2800. In the upper region, resistance lies at 2.0600. The next price resistance is at 2.2800. RSI (Relative Strength Index) is 55.16 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0099, which suggests the price will decrease in the coming days. Percent R is at 25.81%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Better Therapeutics Inc. (BTTX)?
According to Farallon Capital Management LLC filings, the company currently owns 1,147,400 shares, which is about 4.86% of the total BTTX shares outstanding. The investor’s shares have plunged by -202,600 from its previous 13-F filing of 1350000.0 shares. With the completion of the sale, Sectoral Asset Management, Inc.’s stake is now worth $1,590,141. The Vanguard Group, Inc. acquire a 42.81% interest valued at $0.5 million while Victory Capital Management, Inc. 272,720 stake. A total of -107,239 shares of Better Therapeutics Inc. by Alyeska Investment Group LP during the quarter, and 12,500 were bought by Two Sigma Advisers LP. In its current portfolio, Two Sigma Investments LP holds 65,792 shares valued at $0.12 million.